secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-197046
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q2 net loss $54.8M, advances BOT/BAL in CRC; appoints director; files ATM for up to 13.8M shares
--------------------------------------------------------------------------------

- Q2 net loss $54.8M, revenue $23.5M (incl $22.6M non-cash royalty); cash $93.7M at June 30 vs $76.1M Dec 31.
- BOT/BAL in r/r MSS CRC: RECIST ORR 19.4% in selected cohort; 90% 6-month OS; FDA discouraged AA submission; plan to refile with mature data.
- NEST-2 neoadjuvant CRC: 56% (5/9) patients achieved complete pathologic responses; 78% had ≥50% tumor reduction.
- Appointed Thomas L. Harrison to Board as Class III director; granted option for 7,500 shares vesting over 3 years.
- Filed prospectus supplement for ATM offering of up to 13,843,015 shares under existing B. Riley sales agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000119312524197046/0001193125-24-197046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000119312524197046/d800799d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer